Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Sørlie, C. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. Eisen, M. Rijn, S. Jeffrey, T. Thorsen, H. Quist, J. Matese, P. Brown, D. Botstein, P. Lønning, A. Børresen-Dale (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 98
D. Jana, D. Sarkar, Abhiram Maji, B. Chikkala, Syed Hassanujjaman, M. Mukhopadhyay, S. Ganguly (2012)
Can cyclo-oxygenase-2 be a useful prognostic and risk stratification marker in breast cancer?Journal of the Indian Medical Association, 110 7
A. Phipps, R. Chlebowski, R. Prentice, A. McTiernan, M. Stefanick, J. Wactawski‐Wende, L. Kuller, L. Adams-Campbell, D. Lane, M. Vitolins, G. Kabat, T. Rohan, Christopher Li (2011)
Body Size, Physical Activity, and Risk of Triple-Negative and Estrogen Receptor–Positive Breast CancerCancer Epidemiology, Biomarkers & Prevention, 20
A. Prat, C. Perou (2010)
Deconstructing the molecular portraits of breast cancerMolecular Oncology, 5
T. Nielsen, Forrest Hsu, Kristin Jensen, Maggie Cheang, G. Karaca, Zhiyuan Hu, T. Hernandez-Boussard, C. Livasy, D. Cowan, L. Dressler, L. Akslen, J. Ragaz, A. Gown, C. Gilks, M. Rijn, C. Perou (2004)
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast CarcinomaClinical Cancer Research, 10
J. Parker, Michael Mullins, M. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C. Fauron, Xiaping He, Zhiyuan Hu, J. Quackenbush, I. Stijleman, J. Palazzo, J. Marron, A. Nobel, E. Mardis, T. Nielsen, M. Ellis, C. Perou, P. Bernard (2009)
Supervised risk predictor of breast cancer based on intrinsic subtypes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 8
L. Carey, C. Perou, C. Livasy, L. Dressler, D. Cowan, K. Conway, G. Karaca, M. Troester, C. Tse, S. Edmiston, Sandra Deming, J. Geradts, M. Cheang, T. Nielsen, P. Moorman, H. Earp, R. Millikan (2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.JAMA, 295 21
R. Millikan, B. Newman, C. Tse, P. Moorman, K. Conway, L. Dressler, Lisa Smith, M. Labbok, J. Geradts, J. Bensen, S. Jackson, S. Nyante, C. Livasy, L. Carey, H. Earp, C. Perou (2008)
Epidemiology of basal-like breast cancerBreast Cancer Research and Treatment, 109
S. Aebi, Zhuoxin Sun, Danielle Braun, K. Price, M. Castiglione‐Gertsch, M. Rabaglio, R. Gelber, D. Crivellari, J. Lindtner, R. Snyder, P. Karlsson, E. Simoncini, B. Gusterson, G. Viale, M. Regan, A. Coates, A. Goldhirsch (2011)
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.Annals of oncology : official journal of the European Society for Medical Oncology, 22 9
C. Liedtke, C. Mazouni, K. Hess, F. André, A. Tordai, J. Mejia, W. Symmans, A. González-Angulo, B. Hennessy, Marjorie Green, M. Cristofanilli, G. Hortobagyi, L. Pusztai (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 8
G. Tang, S. Shak, S. Paik, S. Anderson, J. Costantino, C. Geyer, E. Mamounas, D. Wickerham, N. Wolmark (2011)
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20Breast Cancer Research and Treatment, 127
S. Braga, L. Lago, C. Bernard, F. Cardoso, M. Piccart (2006)
Use of trastuzumab for the treatment of early stage breast cancerExpert Review of Anticancer Therapy, 6
J. Dignam, V. Dukic, S. Anderson, E. Mamounas, D. Wickerham, N. Wolmark (2009)
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancerBreast Cancer Research and Treatment, 116
T. Sørlie, R. Tibshirani, Joel Parker, T. Hastie, J. Marron, A. Nobel, Shibing Deng, H. Johnsen, Robert Pesich, S. Geisler, J. Demeter, C. Perou, P. Lønning, P. Brown, A. Børresen-Dale, D. Botstein (2003)
Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 100
D. El-Rehim, S. Pinder, C. Paish, J. Bell, R. Blamey, J. Robertson, R. Nicholson, I. Ellis (2004)
Expression of luminal and basal cytokeratins in human breast carcinomaThe Journal of Pathology, 203
C. Sotiriou, S. Neo, L. McShane, E. Korn, Philip Long, A. Jazaeri, P. Martiat, S. Fox, A. Harris, E. Liu (2003)
Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences of the United States of America, 100
K. Voduc, Maggie Cheang, S. Tyldesley, K. Gelmon, Torsten Nielsen, H. Kennecke (2010)
Breast cancer subtypes and the risk of local and regional relapse.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 10
J. Wo, A. Taghian, P. Nguyen, R. Raad, Meera Sreedhara, J. Bellon, J. Wong, M. Gadd, Barbara Smith, J. Harris (2009)
The association between biological subtype and isolated regional nodal failure after breast-conserving therapy.International journal of radiation oncology, biology, physics, 77 1
F. Blows, K. Driver, M. Schmidt, A. Broeks, F. Leeuwen, J. Wesseling, M. Cheang, K. Gelmon, T. Nielsen, C. Blomqvist, P. Heikkilä, T. Heikkinen, H. Nevanlinna, L. Akslen, L. Bégin, W. Foulkes, F. Couch, Xianshu Wang, Victoria Cafourek, J. Olson, L. Baglietto, G. Giles, G. Severi, C. Mclean, M. Southey, E. Rakha, A. Green, I. Ellis, M. Sherman, J. Lissowska, W. Anderson, A. Cox, S. Cross, M. Reed, E. Provenzano, S. Dawson, A. Dunning, Manjeet Humphreys, D. Easton, M. García-Closas, C. Caldas, P. Pharoah, D. Huntsman (2010)
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 StudiesPLoS Medicine, 7
A. Phipps, D. Buist, K. Malone, W. Barlow, P. Porter, K. Kerlikowske, Christopher Li (2011)
Reproductive history and risk of three breast cancer subtypes defined by three biomarkersCancer Causes & Control, 22
M. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. Barrios, G. Steger, C. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Láng, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. Suter, J. Rüschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. Dolci, R. Gelber (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.The New England journal of medicine, 353 16
J. Hugh, J. Hanson, M. Cheang, T. Nielsen, C. Perou, C. Dumontet, J. Reed, M. Krajewska, I. Treilleux, M. Rupin, E. Magherini, J. Mackey, Miguel Martín, C. Vogel (2009)
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 8
D. Berry, C. Cirrincione, I. Henderson, M. Citron, D. Budman, L. Goldstein, S. Martino, E. Perez, H. Muss, L. Norton, C. Hudis, E. Winer (2006)
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerJAMA, 295
D. Slamon, B. Leyland-Jones, Steven Shak, Hank Fuchs, Virginia Paton, A. Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, M. Pegram, J. Baselga, Larry Norton (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.The New England journal of medicine, 344 11
D. Jana, S. Mandal, M. Mukhopadhyay, D. Mitra, S. Mukhopadhyay, D. Sarkar (2012)
Prognostic significance of HER-2/neu and survival of breast cancer patients attending a specialized breast clinic in Kolkata, Eastern India.Asian Pacific journal of cancer prevention : APJCP, 13 8
C. Liedtke, C. Liedtke, K. Broglio, S. Moulder, L. Hsu, S. Kau, W. Symmans, C. Albarracin, F. Meric-Bernstam, W. Woodward, R. Theriault, L. Kiesel, G. Hortobagyi, L. Pusztai, A. González-Angulo (2009)
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 20 12
D. Sarkar, S. Lahiri, Sushil Pandey (2010)
Is estrogen receptor study useful in prognostication of breast cancer patients in India?Indian Journal of Surgical Oncology, 1
C. Carter, Carol Allen, D. Henson (1989)
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer casesCancer, 63
J. Decock, W. Hendrickx, Belle Van, O. Brouckaert, S. Pintens, S. Huffel, R. Paridaens, F. Amant, K. Leunen, A. Smeets, P. Berteloot, E. Limbergen, C. Weltens, W. Bogaert, Benpi Vanden, M. Drijkoningen, H. Wildiers, I. Vergote, R. Christiaens, P. Neven (2007)
Short-Term Prognostic Index for Breast Cancer: NPI or LpiPathology Research International, 2011
A. Onitilo, J. Engel, R. Greenlee, B. Mukesh (2009)
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.Clinical medicine & research, 7 1-2
C. Desmedt, B. Haibe-Kains, P. Wirapati, M. Buyse, D. Larsimont, Gianluca Bontempi, M. Delorenzi, M. Piccart, C. Sotiriou (2008)
Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular SubtypesClinical Cancer Research, 14
K. Albain, W. Barlow, S. Shak, G. Hortobagyi, R. Livingston, I. Yeh, P. Ravdin, R. Bugarini, F. Baehner, N. Davidson, G. Sledge, E. Winer, C. Hudis, J. Ingle, E. Perez, K. Pritchard, L. Shepherd, J. Gralow, C. Yoshizawa, D. Allred, C. Osborne, D. Hayes (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.The Lancet. Oncology, 11 1
B. Haffty, Qifeng Yang, M. Reiss, T. Kearney, S. Higgins, J. Weidhaas, L. Harris, W. Hait, D. Toppmeyer (2006)
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 36
M. Cheang, S. Chia, D. Voduc, D. Gao, S. Leung, J. Snider, M. Watson, S. Davies, P. Bernard, J. Parker, C. Perou, M. Ellis, T. Nielsen (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI Journal of the National Cancer Institute, 101
P. Nguyen, A. Taghian, M. Katz, A. Niemierko, R. Raad, Whitney Boon, J. Bellon, J. Wong, Barbara Smith, J. Harris (2008)
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 14
D. Henson, L. Ries, L. Freedman, M. Carriaga (1991)
Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic indexCancer, 68
A. Albergaria, S. Ricardo, F. Milanezi, V. Carneiro, I. Amendoeira, D. Vieira, J. Cameselle-Teijeiro, F. Schmitt (2011)
Nottingham Prognostic Index in Triple-Negative Breast Cancer: a reliable prognostic tool?BMC Cancer, 11
K. Cronin, S. Plevritis, D. Fryback (2005)
Effect of screening and adjuvant therapy on mortality from breast cancerThe New England Journal of Medicine, 353
Thomas Smith, J. Khatcheressian (2005)
Review: chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancerEvidence Based Medicine, 10
O. Abe, R. Abe, K. Enomoto, K. Kikuchi, H. Koyama, H. Masuda, Y. Nomura, K. Sakai, K. Sugimachi, T. Tominaga, J. Uchino, M. Yoshida, J. Haybittle, C. Davies, V. Harvey, TM Holdaway, R. Kay, B. Mason, J. Forbes, N. Wilcken, M. Gnant, R. Jakesz, M. Ploner, H. Yosef, C. Focan, J. Lobelle, U. Peek, G. Oates, J. Powell, M. Durand, L. Mauriac, A. Leo, S. Dolci, M. Piccart, M. Masood, D. Parker, J. Price, P. Hupperets, S. Jackson, J. Ragaz, D. Berry, G. Broadwater, C. Cirrincione, H. Muss, L. Norton, R. Weiss, H. Abu‐Zahra, S. Portnoj, M. Baum, J. Cuzick, J. Houghton, D. Riley, NH Gordon, H. Davis, A. Beatrice, J. Mihura, A. Naja, Y. Lehingue, P. Romestaing, JB Dubois, T. Delozier, J. Macé-Lesec’h, P. Rambert, O. Andrysek, J. Barkmanova, Owen, P. Meier, A. Howell, G. Ribeiro, R. Swindell, R. Alison, J. Boreham, M. Clarke, R. Collins, S. Darby, P. Elphinstone, Evans, J. Godwin, R. Gray, C. Harwood, C. Hicks, S. James, E. Mackinnon, P. Mcgale, T. McHugh, G. Mead, R. Peto, Y. Wang, J. Albano, Cf Oliveira, H. Gervásio, J. Gordilho, H. Johansen, H. Mouridsen, R. Gelman, Harris, I. Henderson, Claire Shapiro, K. Andersen, C. Axelsson, M. Blichert‐Toft, S. Møller, J. Overgaard, M. Overgaard, C. Rose, B. Cartensen, T. Palshof, H. Trampisch, O. Dalesio, D. Vries, S. Rodenhuis, H. Tinteren, R. Comis, N. Davidson, N. Robert, G. Sledge, D. Tormey, W. Wood, D. Cameron, U. Chetty, P. Forrest, W. Jack, J. Rossbach, J. Klijn, A. Treurniet‐Donker, W. Putten, Alberto Costa, U. Veronesi, H. Bartelink, L. Duchateau, C. Legrand, R. Sylvester, J. Hage, C. Velde, M. Cunningham, R. Catalano, R. Creech, J. Bonneterre, P. Fargeot, P. Fumoleau, P. Kerbrat, M. Namer, W. Jonat, M. Kaufmann, M. Schumacher, G. Minckwitz, G. Bastert, H. Rauschecker, R. Sauer, W. Sauerbrei, A. Schauer, A. Schryver, L. Vakaet, M. Belfiglio, A. Nicolucci, F. Pellegrini, M. Sacco, M. Valentini, C. McArdle, D. Smith, E. Galligioni, F. Boccardo, A. Rubagotti, D. Dent, C. Gudgeon, A. Hacking, A. Erazo, J. Medina, M. Izuo, Y. Morishita, H. Takei, I. Fentiman, J. Hayward, R. Rubens, D. Skilton, H. Graeff, F. Jänicke, C. Meisner, H. Scheurlen, D. Fournier, U. Dafni, G. Fountzilas, P. Klefstrom, C. Blomqvist, T. Saarto, R. Margreiter, B. Asselain, R. Salmon, Vilcoq, R. Arriagada, C. Hill, A. Laplanche, M. Lê, M. Spielmann, P. Bruzzi, E. Montanaro, R. Rosso, Sertoli, M. Venturini, D. Amadori, J. Benraadt, M. Kooi, A. Velde, J. Dongen, J. Vermorken, M. Castiglione, F. Cavalli, A. Coates, J. Collins, J. Forbes, R. Gelber, A. Goldhirsch, J. Lindtner, K. Price, C. Rudenstam, H. Senn, J. Bliss, C. Chilvers, R. Coombes, E. Hall, M. Marty, R. Borovik, G. Brufman, H. Hayat, E. Robinson, N. Wigler, G. Bonadonna, T. Camerini, G. Palo, M. Vecchio, F. Formelli, P. Valagussa, A. Martoni, F. Pannuti, G. Cocconi, A. Colozza, R. Camisa, K. Aogi, S. Takashima, T. Ikeda, K. Inokuchi, K. Sawa, H. Sonoo, S. Korzeniowski, J. Skołyszewski, M. Ogawa, J. Yamashita, J. Bonté, R. Christiaens, R. Paridaens, W. Boegart, P. Martin, S. Romain, T. Hakes, C. Hudis, R. Wittes, G. Giokas, D. Kondylis, B. Lissaios, R. Huerta, MG Sainz, R. Altemus, K. Cowan, D. Danforth, A. Lichter, M. Lippman, J. O’Shaughnessy, L. Pierce, S. Steinberg, D. Venzon, J. Zujewski, A. Paradiso, M. Lena, F. Schittulli, J. Myles, J. Pater, K. Pritchard, S. Anderson, G. Bass, Andrew Brown, J. Bryant, J. Costantino, J. Dignam, B. Fisher, C. Redmond, S. Wieand, N. Wolmark, I. Jackson, M. Palmer, J. Ingle, V. Suman, N. Bengtsson, H. Jonsson, L. Larsson, J. Lythgoe, M. Kissin, B. Erikstein, E. Hannisdal, Abby Jacobsen, J. Varhaug, S. Gundersen, M. Hauer-Jensen, H. Høst, R. Nissen-Meyer, R. Blamey, A. Mitchell, D. Morgan, J. Robertson, M. Palma, G. Mathé, J. Misset, R. Clark, M. Levine, K. Morimoto, Y. Takatsuka, E. Crossley, A. Harris, D. Talbot, Marianne Taylor, B. Blasio, Ivanov, Semiglazov, J. Brockschmidt, Cooper, H. Ueo, C. Falkson, R. a'Hern, S. Ashley, T. Powles, I. Smith, Yarnold, Gazet Jc, N. Cocoran, N. Deshpande, L. Martino, P. Douglas, A. Lindtner, G. Notter, Ajs Bryant, G. Ewing, L. Firth, J. Krushen-Kosloski, L. Foster, W. George, H. Stewart, P. Stroner, P. Malmström, T. Möller, S. Rydén, Tengrup, L. Tennvall-Nittby, J. Carstenssen, M. Dufmats, T. Hatschek, B. Nordenskjöld, M. Söderberg, J. Carpenter, K. Albain, James Crowley, S. Green, S. Martino, C. Osborne, P. Ravdin, U. Glas, U. Johansson, L. Rutqvist, T. Singnomklao, A. Wallgren, R. Maibach, B. Thürlimann, H. Brenner, A. Hercbergs, M. Yoshimoto, G. Deboer, A. Paterson, J. Meakin, T. Panzarella, Y. Shan, Y. Shao, Y Wang, DB Zhao, Zm Chen, HC Pan, J. Bahi, M. Reid, M. Spittle, Gp Deutsch, F. Senanayake, D. Kwong, A. Bianco, C. Carlomagno, M. Laurentiis, S. Placido, A. Buzdar, Thomas Smith, J. Bergh, L. Holmberg, G. Liljegren, J. Nilsson, M. Seifert, P. Sevelda, C. Zielinsky, R. Buchanan, M. Cross, G. Royle, J. Dunn, R. Hills, M. Lee, J. Morrison, D. Spooner, A. Litton, R. Chlebowski, H. Caffier, Ebctcg (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 365
JM Engel AA Onitilo (2009)
BC subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survivalClin Med Res, 7
D. Jana, Soumen Das, D. Sarkar, S. Mandal, Abhiram Maji, M. Mukhopadhyay (2012)
Role of nuclear factor-κB in female breast cancer: a study in Indian patients.Asian Pacific journal of cancer prevention : APJCP, 13 11
J Decock V Belle (2011)
Short-term prognostic index for BC: NPI or LpiPathol Res Int, 4061
Abstract Subtypes are an established prognostic factor of BC in western population but its significance in Indian BC patients has not been evaluated. Thus this study provides an insight into the prognostic significance of molecular classification and its effect on the survival of BC patients in Eastern India. In this hospital based study 242 BC patients attending a Comprehensive Breast Service Clinic of a reputed institute in Eastern India and having IDC were studied over a period of 7 years (January 2007 to October 2013). Nonluminal HER-2-positive and Triple negative tumors were associated with advanced stage of disease, metastatic lymph nodes and NPI ≥5.4, whereas Luminal 1 and Luminal 2 tumors were associated with early stage, uninvolved lymph nodes and NPI <5.4. Better survival was observed for the patients with Luminal 1 [OS = 57.1 % (n = 36)] and Luminal 2 [OS = 60.0 % (n = 6)], compared to Triple negative [OS = 33.6 % (n = 38)] and nonluminal HER-2-positive tumors [OS = 32.1 % (n = 18)]. This study provided some idea about the pattern of BC on the basis of classification by molecular profiling. Our study indicated that Triple negative and nonluminal HER-2-positive tumors have reduced DFS and OS compared with luminal 1 and 2 subtypes. In our patients, Triple negative and nonluminal HER-2-positive tumors were associated with established unfavorable prognostic indicators and this reflects the data in the western literature. The results suggest that the molecular subtypes are an independent prognostic and predictive marker in Indian BC patients. Whether or not molecular subtyping of breast cancer can replace axillary lymph nodes as the standard in prognosis remains to be seen, but if molecular subtyping can provide more information than the axilla about the prognosis and treatment option, it may well be the future of prognostication.
Indian Journal of Surgical Oncology – Springer Journals
Published: Dec 1, 2014
Keywords: surgical oncology; oncology; surgery
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.